Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS

  • Carvajal, René|||0000-0003-3583-8412
  • Guananga-Álvarez, David
  • Tur, Carmen|||0000-0003-1849-3184
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Rodríguez Barranco, Marta|||0000-0001-5454-3041
  • Rando-Segura, Ariadna|||0000-0003-4555-7286
  • Borras Bermejo, Blanca|||0000-0003-4111-5632
  • Cobo-Calvo, Álvaro|||0000-0002-2574-0721
  • Carbonell-Mirabent, Pere|||0000-0003-1349-9261
  • Zules-Oña, Ricardo|||0000-0002-3648-4321
  • Rodrigo-Pendas, Jose Angel|||0000-0003-0400-8766
  • Martínez Gómez, Xavier|||0000-0003-4583-9734
  • Montalban, Xavier|||0000-0002-0098-9918
  • Tintoré, Mar|||0000-0001-9999-5359
  • Otero-Romero, Susana|||0000-0002-6798-568X
BACKGROUND AND OBJECTIVES: Hepatitis B vaccination (HBV) requires 6 months to complete and is recommended for patients with multiple sclerosis (PWMS), particularly those who are candidates for anti-CD20 therapy. However, limited data exist on HBV immunogenicity in PWMS receiving disease-modifying therapies (DMTs) and the impact of starting anti-CD20 therapy during immunization. We aimed to evaluate HBV immunogenicity in PWMS starting anti-CD20 therapy during vaccination, focusing on the number of doses received before anti-CD20 initiation. METHODS: We conducted a retrospective analysis of a prospective cohort of adult PWMS at a single center in Spain, from April 2015 to May 2023. Eligible participants completed a 4-dose HBV course and underwent postvaccination serologic testing. We assess seroprotection rates (SRs), defined as the percentage of patients achieving anti-hepatitis B surface antibody titers ≥10 IU/L, focusing on those who switched to anti-CD20 therapy during vaccination, based on doses received before starting anti-CD20 and type of DMT at vaccination start. A multivariate generalized linear model (GLM) was used to identify factors associated with higher seroconversion. RESULTS: A total of 289 PWMS (median [interquartile range (IQR)] age, 47.7 [42.8-54.4] years; 65.7% female; median [IQR] disease duration, 14.8 [6.7-21.2] years) were included. SRs progressively declined with fewer doses before anti-CD20 initiation, from 92.8% (95% CI 87.1-96.5) for 4 doses to 24.0% (95% CI 9.4-45.1) for 1 dose. Patients transitioning from sphingosine 1-phosphate (S1P) modulators showed the lowest SR at 25.0% (95% CI 7.3-52.4). The multivariate GLM confirmed these findings, with 3 doses (SR ratio 3.23 [95% CI 1.68-6.23]; p = 0.0005) or 4 doses (SR ratio 3.76 [95% CI 1.96-7.24]; p < 0.0001) before anti-CD20 therapy significantly associated with higher SRs, while starting S1P modulators at vaccination onset was significantly associated with lower SRs (SR ratio 0.42 [95% CI 0.23-0.78]; p = 0.0058). Female sex (SR ratio 1.15 [95% CI 1.01-1.32]; p = 0.0389) and younger age (SR ratio 0.90 [95% CI 0.83-0.97]; p = 0.0036) were also significantly associated with higher SRs. DISCUSSION: Initiating anti-CD20 therapy during HBV negatively affects SRs, with a direct correlation with the number of doses received before anti-CD20 initiation. Early planning and execution of required vaccinations are crucial in managing PWMS. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that HBV during initiation of anti-CD20 therapy is less effective in establishing seroprotection to hepatitis B than in patients in whom HBV is completed before initiation of anti-CD20 therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients

  • Carvajal, René|||0000-0003-3583-8412
  • Tur, Carmen|||0000-0003-1849-3184
  • Martínez Gómez, Xavier|||0000-0003-4583-9734
  • Bollo, Luca|||0000-0002-3673-2030
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Rodriguez, Marta
  • Pappolla, Agustin|||0000-0001-6364-9497
  • Cobo-Calvo, Álvaro|||0000-0002-2574-0721
  • Carbonell, Pere
  • Borras-Bemejo, Blanca
  • Río, Jordi|||0000-0003-4546-7627
  • Castilló, Joaquín|||0000-0002-8951-6315
  • Braga, Nathane
  • Mongay-Ochoa, Neus|||0000-0002-0338-4797
  • Rodrigo Pendas, Jose Angel|||0000-0003-0400-8766
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Arrambide, Georgina|||0000-0002-2657-5510
  • Zabalza, Ana|||0000-0003-3860-5251
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Galan, Ingrid|||0000-0001-5774-4260
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Tintoré, Mar|||0000-0001-9999-5359
  • Otero-Romero, Susana|||0000-0002-6798-568X
Mumps-Measles-Rubella (MMR) and Varicella zoster vaccines (VAR) are live attenuated vaccines, usually administered in a two-dose scheme at least 4 weeks apart. However, single-dose immunization schemes may also be effective and can reduce delays in immunosuppressive treatment initiation in patients with multiple sclerosis (pwMS) who need to be immunized. To evaluate the immunogenicity of a single-dose attempt (SDA) versus the standard immunization scheme (SIS) with VAR and/or MMR in pwMS. Retrospective observational study in pwMS vaccinated against VAR and/or MMR. We compared seroprotection rates and antibody geometric mean titers (GMTs) between the two strategies. Ninety-six patients were included. Thirty-one patients received VAR and 67 MMR. In the SDA group, the seroprotection rate was 66.7% (95% confidence interval (CI): 53.3-78.3) versus 97.2% (95% CI: 85.5-99.9) in the SIS (p < 0.001). For the seroprotected patients, GMTs were similar for both schemes. An SDA of VAR and/or MMR vaccines could be sufficient to protect almost two-thirds of patients. Testing immunogenicity after a single dose of VZ and/or MMR could be included in routine clinical practice to achieve rapid immunization.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients

  • Carvajal, René
  • Rodríguez Barranco, Marta
  • Cobo-Calvo, Alvaro
  • Carbonell Mirabent, Pere
  • Rio, Jordi
  • Castillo Justribo, Joaquin
  • Braga da Silva Rezende, Nathane
  • Rodriguez Acevedo, Breogan
  • Zabalza, Ana
  • TUR, CARMEN
  • Martínez-Gómez, Xavier
  • Esperalba, Juliana
  • Pappolla, Agustin
  • BORRAS BERMEJO, BLANCA
  • Rodrigo Pendás, José Ángel
  • Vidal-Jordana, Angela
  • midaglia, luciana
  • Comabella Lopez, Manuel
  • Sastre Garriga, Jaume
  • Tintore, Mar
  • Otero-Romero, Susana
  • Galan, Ingrid
  • Mongay-Ochoa, Neus
  • Arrambide, Georgina
  • Montalban, Xavier
  • Bollo, Luca
Multiple sclerosis; Infections; Vaccination, Esclerosi múltiple; Infeccions; Vacunació, Esclerosis múltiple; Infecciones; Vacunación, Background: Mumps-Measles-Rubella (MMR) and Varicella zoster vaccines (VAR) are live attenuated vaccines, usually administered in a two-dose scheme at least 4 weeks apart. However, single-dose immunization schemes may also be effective and can reduce delays in immunosuppressive treatment initiation in patients with multiple sclerosis (pwMS) who need to be immunized. Objectives: To evaluate the immunogenicity of a single-dose attempt (SDA) versus the standard immunization scheme (SIS) with VAR and/or MMR in pwMS. Methods: Retrospective observational study in pwMS vaccinated against VAR and/or MMR. We compared seroprotection rates and antibody geometric mean titers (GMTs) between the two strategies. Results: Ninety-six patients were included. Thirty-one patients received VAR and 67 MMR. In the SDA group, the seroprotection rate was 66.7% (95% confidence interval (CI): 53.3–78.3) versus 97.2% (95% CI: 85.5–99.9) in the SIS (p < 0.001). For the seroprotected patients, GMTs were similar for both schemes. Conclusion: An SDA of VAR and/or MMR vaccines could be sufficient to protect almost two-thirds of patients. Testing immunogenicity after a single dose of VZ and/or MMR could be included in routine clinical practice to achieve rapid immunization., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI19/01606 and co-funded by the European Union and ECTRIMS clinical fellowship awarded to René Carvajal from 2021 to 2022.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab

  • Carbonell Mirabent, Pere
  • Rodríguez Barranco, Marta
  • Castillo Justribo, Joaquin
  • Guío-Sánchez, Claudia
  • Carvajal, René
  • Zabalza, Ana
  • Martínez-Gómez, Xavier
  • Esperalba, Juliana
  • Pappolla, Agustin
  • Rando Segura, Ariadna
  • Cobo-Calvo, Alvaro
  • TUR, CARMEN
  • Rio, Jordi
  • Comabella Lopez, Manuel
  • Rodrigo Pendás, José Ángel
  • Braga da Silva Rezende, Nathane
  • Vidal-Jordana, Angela
  • Rodriguez Acevedo, Breogan
  • midaglia, luciana
  • BORRAS BERMEJO, BLANCA
  • Sastre Garriga, Jaume
  • Otero Romero, Susana
  • Tintore, Mar
  • Galan, Ingrid
  • Mongay-Ochoa, Neus
  • Arrambide, Georgina
  • Montalban, Xavier
Immunogenicity; Vaccine; Multiple sclerosis, Immunogenicitat; Vacuna; Esclerosi múltiple, Inmunogenicidad; Vacuna; Esclerosis múltiple, Importance Vaccination in patients with highly active multiple sclerosis (MS) requiring prompt treatment initiation may result in impaired vaccine responses and/or treatment delay. Objective To assess the immunogenicity and safety of inactivated vaccines administered during natalizumab treatment. Design, Setting, and Participants This self-controlled, prospective cohort study followed adult patients with MS from 1 study center in Spain from September 2016 to February 2022. Eligible participants included adults with MS who completed immunization for hepatitis B virus (HBV), hepatitis A virus (HAV), and COVID-19 during natalizumab therapy. Data analysis was conducted from November 2022 to February 2023. Exposures Patients were categorized according to their time receiving natalizumab treatment at the time of vaccine administration as short-term (≤1 year) or long-term (>1 year). Main Outcomes and Measures Demographic, clinical, and radiological characteristics were collected during the year before vaccination (prevaccination period) and the year after vaccination (postvaccination period). Seroprotection rates and postvaccination immunoglobulin G titers were determined for each vaccine within both periods. Additionally, differences in annualized relapse rate (ARR), new T2 lesions (NT2L), Expanded Disability Status Scale (EDSS) scores, and John Cunningham virus (JCV) serostatus between the 2 periods were assessed. Results Sixty patients with MS (mean [SD] age, 43.2 [9.4] years; 44 female [73.3%]; 16 male [26.7%]; mean [SD] disease duration, 17.0 [8.7] years) completed HBV, HAV, and mRNA COVID-19 immunization during natalizumab treatment, with 12 patients in the short-term group and 48 patients in the long-term group. The global seroprotection rate was 93% (95% CI, 86%-98%), with individual vaccine rates of 92% for HAV (95% CI, 73%-99%), 93% for HBV (95% CI, 76%-99%), and 100% for the COVID-19 messenger RNA vaccine (95% CI, 84%-100%). Between the prevaccination and postvaccination periods there was a significant reduction in the mean (SD) ARR (0.28 [0.66] vs 0.01 [0.12]; P = .004) and median (IQR) NT2L (5.00 [2.00-10.00] vs 0.81 [0.00-0.50]; P = .01). No changes in disability accumulation were detected (median [IQR] EDSS score 3.5 [2.0-6.0] vs 3.5 [2.0-6.0]; P = .62). No differences in safety and immunogenicity were observed for all vaccines concerning the duration of natalizumab treatment. Conclusions and Relevance The findings of this cohort study suggest that immunization with inactivated vaccines during natalizumab therapy was both safe and immunogenic, regardless of the treatment duration. Natalizumab may be a valuable option for proper immunization, averting treatment delays in patients with highly active MS; however, this strategy needs to be formally evaluated., This study was supported by grants from the European Committee for Treatment and Research in Multiple Sclerosis, Instituto de Salud Carlos III (ISCIII; project PI19/01606), and cofunded by the European Union.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients

  • Carvajal, René
  • Rodríguez Barranco, Marta
  • Cobo-Calvo, Alvaro
  • Carbonell Mirabent, Pere
  • Rio, Jordi
  • Castillo Justribo, Joaquin
  • Braga da Silva Rezende, Nathane
  • Rodriguez Acevedo, Breogan
  • Zabalza, Ana
  • TUR, CARMEN
  • Martínez-Gómez, Xavier
  • Esperalba, Juliana
  • Pappolla, Agustin
  • BORRAS BERMEJO, BLANCA
  • Rodrigo Pendás, José Ángel
  • Vidal-Jordana, Angela
  • midaglia, luciana
  • Comabella Lopez, Manuel
  • Sastre Garriga, Jaume
  • Tintore, Mar
  • Otero-Romero, Susana
  • Galan, Ingrid
  • Mongay-Ochoa, Neus
  • Arrambide, Georgina
  • Montalban, Xavier
  • Bollo, Luca
Multiple sclerosis; Infections; Vaccination, Esclerosi múltiple; Infeccions; Vacunació, Esclerosis múltiple; Infecciones; Vacunación, Background: Mumps-Measles-Rubella (MMR) and Varicella zoster vaccines (VAR) are live attenuated vaccines, usually administered in a two-dose scheme at least 4 weeks apart. However, single-dose immunization schemes may also be effective and can reduce delays in immunosuppressive treatment initiation in patients with multiple sclerosis (pwMS) who need to be immunized. Objectives: To evaluate the immunogenicity of a single-dose attempt (SDA) versus the standard immunization scheme (SIS) with VAR and/or MMR in pwMS. Methods: Retrospective observational study in pwMS vaccinated against VAR and/or MMR. We compared seroprotection rates and antibody geometric mean titers (GMTs) between the two strategies. Results: Ninety-six patients were included. Thirty-one patients received VAR and 67 MMR. In the SDA group, the seroprotection rate was 66.7% (95% confidence interval (CI): 53.3–78.3) versus 97.2% (95% CI: 85.5–99.9) in the SIS (p < 0.001). For the seroprotected patients, GMTs were similar for both schemes. Conclusion: An SDA of VAR and/or MMR vaccines could be sufficient to protect almost two-thirds of patients. Testing immunogenicity after a single dose of VZ and/or MMR could be included in routine clinical practice to achieve rapid immunization., This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI19/01606 and co-funded by the European Union and ECTRIMS clinical fellowship awarded to René Carvajal from 2021 to 2022.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab

  • Carbonell Mirabent, Pere
  • Rodríguez Barranco, Marta
  • Castillo Justribo, Joaquin
  • Guío-Sánchez, Claudia
  • Carvajal, René
  • Zabalza, Ana
  • Martínez-Gómez, Xavier
  • Esperalba, Juliana
  • Pappolla, Agustin
  • Rando Segura, Ariadna
  • Cobo-Calvo, Alvaro
  • TUR, CARMEN
  • Rio, Jordi
  • Comabella Lopez, Manuel
  • Rodrigo Pendás, José Ángel
  • Braga da Silva Rezende, Nathane
  • Vidal-Jordana, Angela
  • Rodriguez Acevedo, Breogan
  • midaglia, luciana
  • BORRAS BERMEJO, BLANCA
  • Sastre Garriga, Jaume
  • Otero-Romero, Susana
  • Tintore, Mar
  • Galan, Ingrid
  • Mongay-Ochoa, Neus
  • Arrambide, Georgina
  • Montalban, Xavier
Immunogenicity; Vaccine; Multiple sclerosis, Immunogenicitat; Vacuna; Esclerosi múltiple, Inmunogenicidad; Vacuna; Esclerosis múltiple, Importance Vaccination in patients with highly active multiple sclerosis (MS) requiring prompt treatment initiation may result in impaired vaccine responses and/or treatment delay. Objective To assess the immunogenicity and safety of inactivated vaccines administered during natalizumab treatment. Design, Setting, and Participants This self-controlled, prospective cohort study followed adult patients with MS from 1 study center in Spain from September 2016 to February 2022. Eligible participants included adults with MS who completed immunization for hepatitis B virus (HBV), hepatitis A virus (HAV), and COVID-19 during natalizumab therapy. Data analysis was conducted from November 2022 to February 2023. Exposures Patients were categorized according to their time receiving natalizumab treatment at the time of vaccine administration as short-term (≤1 year) or long-term (>1 year). Main Outcomes and Measures Demographic, clinical, and radiological characteristics were collected during the year before vaccination (prevaccination period) and the year after vaccination (postvaccination period). Seroprotection rates and postvaccination immunoglobulin G titers were determined for each vaccine within both periods. Additionally, differences in annualized relapse rate (ARR), new T2 lesions (NT2L), Expanded Disability Status Scale (EDSS) scores, and John Cunningham virus (JCV) serostatus between the 2 periods were assessed. Results Sixty patients with MS (mean [SD] age, 43.2 [9.4] years; 44 female [73.3%]; 16 male [26.7%]; mean [SD] disease duration, 17.0 [8.7] years) completed HBV, HAV, and mRNA COVID-19 immunization during natalizumab treatment, with 12 patients in the short-term group and 48 patients in the long-term group. The global seroprotection rate was 93% (95% CI, 86%-98%), with individual vaccine rates of 92% for HAV (95% CI, 73%-99%), 93% for HBV (95% CI, 76%-99%), and 100% for the COVID-19 messenger RNA vaccine (95% CI, 84%-100%). Between the prevaccination and postvaccination periods there was a significant reduction in the mean (SD) ARR (0.28 [0.66] vs 0.01 [0.12]; P = .004) and median (IQR) NT2L (5.00 [2.00-10.00] vs 0.81 [0.00-0.50]; P = .01). No changes in disability accumulation were detected (median [IQR] EDSS score 3.5 [2.0-6.0] vs 3.5 [2.0-6.0]; P = .62). No differences in safety and immunogenicity were observed for all vaccines concerning the duration of natalizumab treatment. Conclusions and Relevance The findings of this cohort study suggest that immunization with inactivated vaccines during natalizumab therapy was both safe and immunogenic, regardless of the treatment duration. Natalizumab may be a valuable option for proper immunization, averting treatment delays in patients with highly active MS; however, this strategy needs to be formally evaluated., This study was supported by grants from the European Committee for Treatment and Research in Multiple Sclerosis, Instituto de Salud Carlos III (ISCIII; project PI19/01606), and cofunded by the European Union.